Through investment and partnership, Pathway to Cures encourages early-stage biotech companies to develop treatments that have the potential to improve the lives of people in our community.
Since Pathway to Cures (P2C) launched in 2023, more than 200 early-stage biotechnology, pharma, medical device and diagnostic companies, with innovative approaches that address unmet needs in our blood and bleeding disorders community, have been reviewed by our team.
As a result, P2C has invested in five companies. These companies are at different stages of development, deploying a range of technologies, including:
- cellular medicine platform with engineered B-cells
- genetic medicines platform with non-viral but virus inspired DNA delivery
- drug target identification for ASOs (antisense oligonucleotides)
- small molecules
- non-invasive medical devices
Learn more about these companies here.
Any investment we make is used for areas of treatment relevant to our community. Companies that are using new technologies for the development of any treatments and cures must decide which therapeutic areas to prioritize. Through our relationships with investors and companies in our pipeline, Pathway to Cures encourages companies to focus on at least one blood or bleeding disorder treatment.
Working with other investors is critical to our success. There are many more companies that qualify for and deserve investment than we are able to support. So, as we work to find additional resources to invest, we also work to find other investors to support these programs.
Also, it takes more funding than we can provide for these companies to be successful. So, it is imperative that we work effectively with other investors to ensure that the companies in our portfolio have the resources for the development of therapies and cures. We also feel it is important to demonstrate to other venture funds the value of investing in companies developing therapies and cures for bleeding disorders.
As we build these investor relationships, we are finding that traditional investors are interested in having Pathway to Cures as a co-investor, even though our financial investment is small. They value our evaluation process which reflects NBDF’s understanding of bleeding disorders, the needs of this patient population and access to key opinion leaders.
Pathway to Cures is powered by more than 15+ experts in science, medicine, finance, business and governance, as well as many talented staff at NBDF.
Importantly, the program is supported by generous donors who understand that their gift is one that keeps on giving. The returns from their donation are reinvested in further innovation, education and advocacy to benefit the blood and bleeding disorders community.
At Pathway to Cures, venture philanthropy means we combine expertise with hope. We apply best practices in early-stage investing to advance medical innovation, supporting the National Bleeding Disorders Foundation mission to find cures, and transform the lives of people living with blood and bleeding disorders.
Watch a video about venture philanthropy here.
Teri Willey, Managing Director & Officer, Pathway to Cures, NBDF
Tim, Brent, Venture Principal, Pathway to Cures, NBDF
The National Bleeding Disorders Foundation Venture Fund, LLC (Pathway to Cures) exists to support NBDF in enabling cures for inheritable blood and bleeding disorders and to address and prevent the complications of these disorders. Furthermore, we are here to create future revenue sources to ensure NBDF continues to support the blood and bleeding disorders community through innovation, education, advocacy and research. www.pathwaytocures.org
